Cadrenal Therapeutics, Inc. Common Stock (CVKD) — Capital Reinvestment Ratio

Latest as of September 2022: 2.25x

Cadrenal Therapeutics, Inc. Common Stock (CVKD) has a Capital Reinvestment Ratio of 2.25x as of September 2022, meaning it reinvests 2% of its operating cash flow ($1.01K) in capital expenditures ($2.28K). Check Cadrenal Therapeutics, Inc. Common Stock (CVKD) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

2.25x

Capex / Operating Cash Flow

Operating Cash Flow

$1.01K

USD

Capital Expenditures

$2.28K

USD

Data as of

Sep 2022

Most recent filing

Annual Capital Reinvestment Ratio for Cadrenal Therapeutics, Inc. Common Stock (None–None)

Year-by-year Capital Reinvestment Ratio for Cadrenal Therapeutics, Inc. Common Stock from None to None. See CVKD free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (USD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow